Earnings ·
BridgeBio Oncology Therapeutics reported financial results for the quarter ended June 30, 2026
BBOTBridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics reported financial results for the quarter ended June 30, 2026. The company incurred a net loss of $56.5 million and spent $49.2 million on research and development, driven by increased clinical trial costs. General and administrative expenses rose to $11.0 million due to standalone operations following its de-SPAC transaction. As of June 30, the firm held $344.1 million in cash and marketable securities, providing a runway into 2028. Clinically, BBOT initiated dosing for BBO-11818 with cetuximab and presented preclinical data at AACR. BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting RAS-pathway malignancies.